- Development of donepezil-induced hypokalemia following treatment of cognitive impairment
-
Dongryul Kim, Hye Eun Yoon, Hoon Suk Park, Seok Joon Shin, Bum Soon Choi, Byung Soo Kim, Tae Hyun Ban
-
Yeungnam Univ J Med. 2021;38(1):65-69. Published online June 1, 2020
-
DOI: https://doi.org/10.12701/yujm.2020.00269
-
-
6,300
View
-
136
Download
-
1
Crossref
-
 Abstract
 PDF
- Donepezil is a cholinesterase inhibitor used extensively to treat Alzheimer disease. The increased cholinergic activity is associated with adverse effects, therefore gastrointestinal symptoms, including nausea, vomiting, and diarrhea, are common. Hypokalemia is a rare adverse event that occurs in less than 1% of donepezil-treated patients. Although hypokalemia of mild and moderate grade does not present serious signs and symptoms, severe hypokalemia often results in prolonged hospitalization and mortality. Herein, we report a case of hypokalemia developed after the initiation of donepezil therapy for cognitive impairment.
-
Citations
Citations to this article as recorded by  - Thymus vulgaris Essential Oil Protects Zebrafish against Cognitive Dysfunction by Regulating Cholinergic and Antioxidants Systems
Luminita Capatina, Elena Todirascu-Ciornea, Edoardo Marco Napoli, Giuseppe Ruberto, Lucian Hritcu, Gabriela Dumitru
Antioxidants.2020; 9(11): 1083. CrossRef
|
E-Submission
Yeungnam University College of Medicine
